The world needs better pain treatments

Pain is widely considered as one of the biggest problems in medicine today: a 2016 UK-based review indicates that an estimated 28 million adults in the UK suffer from chronic pain 1. Adequate treatment is often unavailable or hard to access, and as a specialist business focused on this market niche, we’re determined to tackle this problem.

1 Fayaz A, Croft P, Langford RM, et al. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open 2016;6:e010364.doi:10.1136/bmjopen-2015-010364

“Imagine going through your daily life where everything that you touch, or that touches you, where almost every noise around you from a passing car to children playing, causes you pain. We will leave no stone unturned to help these patients.”

Gabriel Baertschi

Chief Executive Officer

Our purpose is to change lives for the better. We believe that change is possible. We invest heavily in innovation, exploring new possibilities to develop smart solutions. Success comes from pioneering treatments that transform patients’ lives for the better. This measure of success drives everything we do.


Our strategy: leading with innovation

We focus our R&D activities on pain and have built up our portfolio with projects beyond pain and medical devices. This diversifies our risks and opens new markets for us.


“As a worldwide leader in pain management, we are looking for strategic partnerships in research and development to bring innovative solutions to patients with indications with high unmet medical needs. Innovation is at our core and as a fully integrated pharmaceutical company, we can offer support along the whole value chain – from drug development to commercialisation.”

Gabriel Baertschi

Chief Executive Officer

Get to know us

Grunenthal Ltd., UK, a subsidiary of Grunenthal GmBH, was established in 2004. With headquarters in Maidenhead, the company includes Regulatory, Medical Information, Sales and Marketing divisions as well as Market Access and Medical Science Liaison teams.

Grunenthal Ltd., UK currently markets medications for relief or management of moderate to severe pain including peripheral neuropathic pain to GPs, hospital doctors, pharmacists and nurses.

Grünenthal Headquarters, Aachen Germany

Grünenthal by the numbers

We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 27 countries with affiliates in Europe, Latin America and the USA.


A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach alongside a commitment to diversity and inclusivity.

Ready to create a brighter future for our patients?  - Work with Grünenthal

Join us

Imaginative researcher? Unconventional strategist? Forward-thinking go-getter? We would love to hear from you.

M-NA-UK-03-24-0032 - March 2024